Solaxa

Solaxa

Early Stage

Restoring people's lives suffering from nerve dysfunction with FDA approved drug

Restoring people's lives suffering from nerve dysfunction with FDA approved drug

Overview

Raised to Date: Raised: $0

Total Commitments ($USD)

Platform

Wefunder

Start Date

05/23/2023

Close Date

07/25/2023

Min. Goal
$50,000
Max. Goal
$1,200,000
Min. Investment

$100

Security Type

SAFE

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Early Bird Val. Cap

$12,500,000

Valuation Cap

$15,000,000

Discount

10%

Rolling Commitments ($USD)

Status
Not Funded
Reporting Date

07/25/2023

Days Remaining
Not Funded
% of Min. Goal
Not Funded
% of Max. Goal
Not Funded
Likelihood of Max
Not Funded
Avg. Daily Raise

$0

Momentum
Not Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2021

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B2C

Margin

Medium

Capital Intensity

High

Location

BETHESDA, Maryland

Business Type

Growth

Solaxa, with a valuation of $15 million, is raising funds on Wefunder. The company is revolutionizing the treatment of nerve dysfunction with its FDA-approved drug. The company is clinical-stage ready and neuro-focused and is developing better treatments for hereditary ataxias and nerve injury. The drug targeting nerve dysfunction caused by hereditary ataxia is called Ampyra or dalfampridine and is already FDA-approved to improve walking in adults with multiple sclerosis. Christian Walker founded Solaxa in February 2021. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1.2 million. The campaign proceeds will be used for salaries, consulting and legal services to obtain orphan drug designation, pre-clinical research and development, product development and manufacturing, and company operations.

Summary Profit and Loss Statement

FY 2022 FY 2021

Revenue

$0

$0

COGS

$0

$0

Tax

$1,550

$0

 

 

Net Income

$-200,342

$-17,652

Summary Balance Sheet

FY 2022 FY 2021

Cash

$287

$55,026

Accounts Receivable

$0

$0

Total Assets

$319,840

$72,358

Short-Term Debt

$302,262

$0

Long-Term Debt

$84,062

$0

Total Liabilities

$386,324

$0

Financials as of: 05/23/2023
Create a free account today to gain access to KingsCrowd analytics.

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Solaxa on Wefunder 2023
Platform: Wefunder
Security Type: SAFE
Valuation: $15,000,000

Follow company

Follow Solaxa on Wefunder 2023

Buy Solaxa's Deal Report

Warning: according to the close date for this deal, Solaxa may no longer be accepting investments.

Solaxa Deal Report

Get KingsCrowd’s comprehensive report on Solaxa including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Solaxa is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Solaxa deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge